LMT 10th Birthday 2022
To celebrate Lung Cancer Management 10th Birthday, we are offering a 25% discount on article processing fees until the end of 2022. Submit your article today!
Related Articles
Biomedical publisher Future Science Group joins Taylor & Francis
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Biomedical publisher Future Science Group joins Taylor & Francis
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Biomedical publisher Future Science Group joins Taylor & Francis
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
CRC 10th Birthday
To celebrate Colorectal Cancers10th Birthday, we are offering a 25% discount on article processing fees until the end of 2022. Submit your article today!
CNS 10th Birthday
To celebrate CNS Oncology 10th Birthday, we are offering a 25% discount on article processing fees until the end of 2022. Submit your article today!
FSG OA Week 2022
To celebrate Open Access Week 2022, we are offering a 50% discount on article processing fees. Submit your article today!
Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC | Future Oncology
The rapid development of molecular targeted therapy brings hope to patients with advanced non-small-cell lung cancer (NSCLC). However, drug resistance inevitably occurs during treatment with EGFR-tyrosine…
Biopsy frequency and complications among lung cancer patients in the United States | Lung Cancer Management
Objective: This study aimed to describe the frequency and distribution of biopsy procedures for patients diagnosed and treated for primary lung cancer. Study design: Retrospective…
New platinum chemotherapy in development with promising preclinical results – Oncology Central
Platinum chemotherapy candidate currently undergoing development is showing reduced toxicity and fewer side effects in preclinical trials.
Lung Cancer Management | Vol 9, No 3
We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.× Password Changed Successfully Your…